Economic evaluation of sublingual vs subcutaneous allergen immunotherapy (Q42657579)

4 November 2017

title

Economic evaluation of sublingual vs subcutaneous allergen immunotherapy (English)

1 reference

4 November 2017

1 reference

Jitka Pokladnikova

1

1 reference

4 November 2017

Irena Krcmova

series ordinal

2

1 reference

4 November 2017

Jiri Vlcek

series ordinal

3

1 reference

4 November 2017

publication date

1 May 2008

1 reference

Annals of Allergy, Asthma & Immunology

4 November 2017

published in

1 reference

4 November 2017

volume

100

1 reference

4 November 2017

issue

5

1 reference

4 November 2017

page(s)

482-489

1 reference

Allergic rhinitis and its impact on asthma

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

The economic burden of allergic rhinitis: a critical evaluation of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Long-lasting clinical efficacy of allergen specific immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Interpretation of rhinoconjunctivitis quality of life questionnaire data

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

How to calculate indirect costs in economic evaluations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Allergic rhinitis and its impact on asthma update: allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Anaphylaxis to multiple pollen allergen sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

The safety of sublingual-swallow immunotherapy: an analysis of published studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Determinants of patient compliance with allergen immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Quantitative assessment of the adherence to sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year)

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960475-9

7 January 2021

10.1016/S1081-1206(10)60475-9

Identifiers

DOI

1 reference

4 November 2017

1 reference